Even after the additional adjustments for hypertension, dyslipidemia, overweight or obesity, T2DM, LDL, AST, ALT, and creatinine, participants with MAFLD still had a higher risk in the development of new incidents of CKD (adjusted HR 1.18, 95% CI 1.11-1.26). This evidence concerns the gene GPT and obesity due to melanocortin 4 receptor deficiency.